Exhibit
10.34.2


 


Certain identified information
has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly
disclosed. [***] indicates that information has been redacted.


 


Amendment 1


to the Exclusive International Distribution
Agreement (“EIDA”)


dated October 5, 2015


entered into as of November 15, 2017 (“Effective
Date”)


by and between


Curetis GmbH and Acumen Research Laboratories
Pte Ltd (collectively the Parties)


The Parties agree to amend the aforementioned
EIDA as follows:




		·	Distributor agrees to distribute the Unyvero BCU application in the Territory and such cartridges
to become part of the Products list of the EIDA. The enclosed updated Attachment 1.1 (A) “Products” shall supersede
the original Attachment 1.1(A).



		·	Distributor agrees to participate in BCU application training combined with a software training.



		·	Distributor will ensure a timely update of any marketing materials affected by the product release
of the Unyvero BCU cartridge and new software. Curetis shall support this effort and shall provide distributor with samples of
advertising and other promotional material in the English language free of charge.



		·	Curetis will make available to Distributor the relevant Unyvero software free of charge upon completion
of the aforementioned training and fulfilment of any regulatory prerequisites in Territory.



		·	Distributor shall install the software upgrade and provide necessary customer training to any customer
prior to providing Unyvero BCU cartridges.



		·	Distributor will include the Unyvero BCU cartridge forecasting in the next regular forecast following
the Effective Date of this amendment.



		·	Enclosed Attachment 7.1 “Prices” shows the current Curetis distributor transfer price
list (as of January 1, 2017), including the transfer pricing for the Unyvero BCU blood culture application and shall supersede
the original Attachment 7.1.



		·	Enclosed Attachment 11.1 “Storage Conditions” shall supersede the original Attachment
11.1.



		·	The following shall become part of the EIDA as section 2.1 (p): “Distributor shall inform
Curetis about the intention of a customer in the territory to set up a trial/study with the



 


    	 




    	 



    


 





Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.


 


 







Unyvero system. Curetis shall use
its best efforts to support the customer in issues related to such trial/study. Distributor is obliged, should one of his customers
intend to publish data arisen from such a trial/study, to make available to Curetis in compliance with applicable patient data
protection laws, rules and regulations, the data as well as manuscripts based on these data thirty (30) days prior to submission
for publication for review, comment and approval. Customer will consider Curetis’ comments for integration into the manuscripts
provided that they are factually correct and do not compromise the scientific quality and integrity of the publication. Curetis
agrees not to deny approval without serious cause.”.


		·	The original Section 28 “final provisions” of the EIDA now becomes Section 30 and a
new Section 28 “Compliance” shall be inserted:



“COMPLIANCE


		28.1	In 2015 Curetis Code of Conduct was first passed and put into practice. It sets forth our standards
to promote honest and ethical conduct with all of Curetis’ stakeholders, including its Distributors. It is binding for all
employees of Curetis worldwide and covers among others conflicts of interest, gifts or entertainment, protecting privacy and confidentiality
as well as fraud, dishonesty or criminal conduct. Our Code is supplemented by further policies on specific areas and is part of
Curetis’ constant endeavor to ensure its commitment to lawful and ethical behavior. Therefore, and to take along the Distributor
in this endeavor, Distributor agrees to observe the regulations of Curetis Code of Conduct, which can easily be found on Curetis
homepage.



		28.2	The Distributor is aware that he might be dealing with (foreign) officials that are subject to
anti-bribery and anti-corruption laws while performing his services. Accordingly, the Distributor hereby represents and warrants
that:



		(a)	Distributor is in compliance with the applicable laws, especially any anti-bribery and anti-corruption
laws and will remain in compliance with all such at least for the duration of the Agreement.



		(b)	Distributor has not taken and will not take any actions in furtherance of an offer, payment, promise
to pay, or authorization of the payment or giving of money, or anything else of value, to any government official (including any
officer or employee of any government or government-controlled entity or of a public international organization, or any person
acting in an official or representative capacity for or on behalf of any of the foregoing, or any political party or official thereof,
or candidate for political office, or legislative, administrative or judicial officials whether or not elected or appointed, all
of the foregoing being referred to as “Government Officials”) or to any other person while knowing that all or some
portion of the money or value will be offered, given or promised to a Government Official for the purposes of obtaining or retaining
business, an advantage in the conduct of business, securing any improper advantage or improper performance of that person’s
function or misuse of its position.



		28.3	In connection with the foregoing representations and warranties of Section 28.2, the Parties further
agree as follows:


 



    	2 




    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 




    


		(a)	When a situation arises indicating a possible breach of the foregoing representations and warranties
of this article by the Distributor, the Distributor permits CURETIS to conduct an audit of its records and books of account related
to this Agreement only, during normal business hours. The Distributor supports the audit to the best of its abilities, especially
in granting free access to a room on its business premises for the audit to take place there and in supplying all details, reports,
data and other information relating to this Agreement as CURETIS may reasonably request.



		(b)	In the event of a breach the Distributor shall indemnify and hold harmless the Principal against
any and all claims, losses or damages arising from or related to such breach or cancellation of this contract.”



		·	A new Section 21.5 shall be inserted into the EIDA: “In addition, this Agreement may be terminated
by CURETIS with immediate effect, if the Distributor is in breach of Section 28 (Compliance).”



All other clauses of the EIDA shall
remain unchanged and in full force and effect.


	
        Curetis GmbH

        represented by:

         

         

        /s/ Achim Plum
	 	
        Acum Research Labortories Pte Ltd

        represented by:

         

         

        /s/ Siew Hwa Ong

	 
	
        Name: Dr. Achim Plum

        Title: Managing Director

        Date: 22 Nov 2017

         

         

        /s/ Oliver Schacht
	 	
        Name: Siew Hwa Ong, PhD

        Title: Managing Director

        Date: 15 Nov 2017

         

         

        /s/ Li Ywanhan

	 
	Name: Oliver Schacht, Ph.D.

Title: Managing Director

Date: 22 Nov 2012	 	Name: Li Ywanhan

Title: Research Associate

Date: 15 Nov 2017


 


Enclosure: new attachments 1.1 (A) –
Products; 7.1– Prices; 11.1 - Storage Conditions




    	3 




    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 




    


 


ATTACHMENT 1.1(A)


PRODUCTS


I.       Curetis
Unyvero Solution consisting of:


		·	1x Unyvero A50 Analyzer (Article-No.: 60001)



		·	lx Unyvero L4 Lysator (Article-No.: 60002)



Includes:
1 Unyvero Sample Tube holder


		·	lx Unyvero C8 Cockpit (Article-No.: 60003)



II.       1
Unyvero P55/HPN Cartridge Set (Article-No.: 10047) Includes:


		·	12x Unyvero P55/HPN Pneumonia Cartridge



		·	12x Unyvero T1 Sample Tube (Article-No.: 10012), with lysis reagents



		·	12x Unyvero T1 Sample Tube Cap (Article-No.: 10013), includes quality control



		·	12x Unyvero Tl Sample Transfer Tool (Article-No.: 10014), special sample pipetting aid



III.       1
Unyvero i60/ITI Cartridge Set (Article-No.: 10041) Includes:


		·	12x Unyvero ITI Cartridge



		·	12x Unyvero T1 Sample Tube (Article-No.: 10012), with lysis reagents



		·	12x Unyvero T1 Sample Tube Cap (Article-No.: 10013), includes quality control



		·	12x Unyvero T1 Sample Pretreatment Tool (Article-No.: 10043)



IV       1
Unyvero BCU Cartridge Set (Article-No.: 10051) Includes:


		·	12x Unyvero BCU Cartridge



		·	12x Unyvero B1 Sample Tube (Article-No.: 10063), with lysis reagent



		·	12x Unyvero B1 Sample Tube Cap (Article-No.: 10062), includes quality control





    	4 




    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 




    


		·	12x Unyvero B1 Collection Tube (Article-No.: 10061), handling tool to pipette required sample volume



V.       1
Unyvero M1 Master Mix Tube (Article-No.: 10011) Includes:


		·	12x Unyvero M1 Master Mix Tube (10002)



 
 


    	5 




    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 




    


 


ATTACHMENT 7.1

TRANSFER PRICES


[***]


 






    	6 




    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 




    

 


ATTACHMENT 11.1

STORAGE CONDITIONS


	
        Unyvero

        L4 Lysators
	18 °C to 35 °C
	
        Unyvero

        C8 Cockpits
	18°C to 35°C
	
        Unyvero

        A50 Analyzers
	18°C to 35°C
	
        Unyvero

        P55/HPN Hospitalised
        Pneumonia Sets (excl. M1 Master Mix)
	15°C to 25°C
	
        Unyvero

        i60/ITI Sets (excl.
        M1 Master Mix)
	15°C to 25°C
	
        Unyvero

        BCU Sets (excl. M1
        Master Mix
	15°C to 25°C
	
        UnyveroTM M1
        Master Mix

         
	-20°C long term (> 7d), up to +4 °C short term (<7d)


 


Or as otherwise described in the then
current version of the applicable Instructions for Use of the respective Product as provided in writing by Curetis to Distributor.
In case of ambiguity, the last version of the applicable Instructions for Use of the respective writing by Curetis to Distributor
shall prevail.


 






    	7 




    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.